跳至主要内容
临床试验/JPRN-jRCT2031190034
JPRN-jRCT2031190034已完成1 期

A Phase I/II study of mucosal immunotherapy using HPV-targeting Lactobacillus-based vaccine, IGMKK16E7, for treatment of HPV16-related high-grade squamous intraepithelial lesions: MILACLE study - MILACLE study

Kawana Kei0 个研究点目标入组 165 人开始时间: 2019年5月31日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
165

研究概览

简要总结

In a double-blind, placebo-controlled, randomized trial, 165 patients with HPV16-positve high-grade cervical intraepithelial neoplasia (CIN2/3) were assigned to orally-administered placebo, or low-, intermediate-, or high-doses of IGMKK16E7 (lacticaseibacillus paracasei expressing cell surface, full-length HPV16E7). In all four groups, IGMKK16E7 or placebo was administered orally at weeks 1, 2, 4 and 8 post-enrollment. The primary outcomes included histopathological regression and IGMKK16E7 safety.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 45age old(—)
性别
Female

入选标准

  • 20-45 years-old health female who are diagnosed as HSIL/CIN2 and HSIL/CIN3 by histological examination and infected with HPV 16 alone or HPV16+other types.

排除标准

  • (1) Immune compromised host or person who receive immunosuppressive therapy,
  • (2) Patients who is suspected as invasive cancer,
  • (3) Patients who has a previous history of hypersensitivity to Lactobacillus-content food/drug or milk,
  • (4) Pregnant women or patients who expected to get pregnant,
  • (5) Breast feeder mother.

研究者

发起方
Kawana Kei

相似试验

A Phase I/II study of mucosal immunotherapy using... | 临床试验